Announcement on Acquisition and Retirement of Own Shares
(Acquisition of Own Shares pursuant to the Provisions of Paragraph 2, Article 165 of the Companies Act
and Retirement of Own Shares pursuant to the Provisions of Article 178 of the Companies Act)
Osaka, Japan, July 25, 2023 - Ono Pharmaceutical Co., Ltd. (President and CEO: Gyo Sagara; “the Company”) today announced that in accordance with Article 370 (resolution by documents instead of resolution by board meetings) of the Companies Act, it has resolved to acquire its own shares under the provisions of Article 156 of the Companies Act, applied by the replacing terms pursuant to the provisions of Paragraph 3, Article 165 of the Companies Act, and retire own shares pursuant to the provisions of Article 178 of the Companies Act.
- Reasons for the acquisition and retirement of own shares
The Company will acquire own shares in order to shareholder return, taking into future financial condition, common stock price and other factors.
- Contents of the acquisition
（1） Class of shares to be acquired ：Common stock of the Company （2） Total number of shares to be acquired ：19 million shares (maximum)
(3.89% of the total outstanding shares excluding own shares)（3） Total amount of acquisition cost ：¥50.0 billion yen (maximum) （4） Period of acquisition ：August 1, 2023 to March 22, 2024 （5） Method for acquisition ：Purchase on the Tokyo Stock Exchange （6） Schedule after acquisition ：All the common stock acquired will be retired. - Contents of the retirement
（1） Class of shares to be retired ：Common stock of the Company （2） Total number of shares to be retired ：All the common stock acquired in accordance with section 2 above. （3） Scheduled date of retirement ：March 29 ,2024 (planned)
(Reference) The status of own shares as of March 31, 2023
| Total number of shares issued (excluding own shares) |
：488,399,246 shares |
| Total number of own shares | ：29,025,954 shares |